ESC Premium Access

Interactive discussion: what are the implications of SGLT2 inhibition for CV risk reduction in a multi-risk patient population?

Topic: Diabetes management
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly

Congress Presentation

About the speakers

Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)
52 presentations

Professor Silvio Inzucchi

New Haven (United States of America)
5 presentations
0 follower

2 more presentations in this session

Introduction - SGLT2 inhibition in the management of CV risk & T2DM: ask the experts.

Speaker: Professor J. Deanfield (London, GB)


SGLT-2 inhibitors in the management of CVD and T2DM: brief update on results of the EMPA-REG OUTCOME trial.

Speaker: Professor S. Inzucchi (New Haven, US)


Access the full session

SGLT2 inhibition in the management of CV risk & T2DM: ask the experts

Speakers: Professor J. Deanfield, Professor S. Inzucchi, Professor J. Deanfield, Professor S. Inzucchi

About the event


ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb